Feiying Gu

451 total citations
11 papers, 316 citations indexed

About

Feiying Gu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Feiying Gu has authored 11 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 3 papers in Surgery. Recurrent topics in Feiying Gu's work include Lung Cancer Diagnosis and Treatment (3 papers), Esophageal and GI Pathology (2 papers) and Gastric Cancer Management and Outcomes (2 papers). Feiying Gu is often cited by papers focused on Lung Cancer Diagnosis and Treatment (3 papers), Esophageal and GI Pathology (2 papers) and Gastric Cancer Management and Outcomes (2 papers). Feiying Gu collaborates with scholars based in China. Feiying Gu's co-authors include Yuezhen Wang, Jun Fang, Zhigang Chen, Feng Chen, Dong Liu, Jun Fang, Xiaoxin Wu, Zhun Wang, Huiyin Lan and Yuxin Lin and has published in prestigious journals such as Cellular and Molecular Life Sciences, Frontiers in Oncology and Stem Cell Research & Therapy.

In The Last Decade

Feiying Gu

10 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Feiying Gu China 10 133 106 94 55 54 11 316
Xiangshan Yang China 12 133 1.0× 76 0.7× 70 0.7× 72 1.3× 42 0.8× 21 295
Giulia Sorgentoni Italy 10 74 0.6× 78 0.7× 70 0.7× 72 1.3× 57 1.1× 16 268
Matthew Kosel United States 8 123 0.9× 72 0.7× 66 0.7× 70 1.3× 25 0.5× 20 274
Ali Hussain United States 5 129 1.0× 65 0.6× 55 0.6× 46 0.8× 40 0.7× 5 278
Gaurav Kumar United States 9 153 1.2× 62 0.6× 104 1.1× 28 0.5× 59 1.1× 10 314
Elsa M. Li-Ning-Tapia United States 5 78 0.6× 129 1.2× 146 1.6× 97 1.8× 43 0.8× 6 313
Huiyu Lu China 11 120 0.9× 144 1.4× 82 0.9× 76 1.4× 23 0.4× 29 303
Jörg Kumbrink Germany 10 90 0.7× 108 1.0× 80 0.9× 89 1.6× 25 0.5× 37 325
Jinghui Wang China 11 113 0.8× 208 2.0× 174 1.9× 64 1.2× 54 1.0× 57 441

Countries citing papers authored by Feiying Gu

Since Specialization
Citations

This map shows the geographic impact of Feiying Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feiying Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feiying Gu more than expected).

Fields of papers citing papers by Feiying Gu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feiying Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feiying Gu. The network helps show where Feiying Gu may publish in the future.

Co-authorship network of co-authors of Feiying Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Feiying Gu. A scholar is included among the top collaborators of Feiying Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feiying Gu. Feiying Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Zhou, Xia, et al.. (2023). Neoadjuvant immune checkpoint inhibitor therapy and chemotherapy improve pulmonary ventilation and diffusion function in patients with lung cancer. Journal of Zhejiang University (Medical Sciences). 52(5). 588–593.
2.
Fang, Jun, et al.. (2022). MiR-125b-5p/TPD52 Axis Affects Proliferation, Migration and Invasion of Breast Cancer Cells. Molecular Biotechnology. 64(9). 1003–1012. 12 indexed citations
3.
Fang, Jun, Feng Chen, Dong Liu, Feiying Gu, & Yuezhen Wang. (2021). Adipose tissue-derived stem cells in breast reconstruction: a brief review on biology and translation. Stem Cell Research & Therapy. 12(1). 8–8. 34 indexed citations
4.
Zhou, Ning, Juan Lin, Jun Fang, et al.. (2021). Outcomes of SBRT for lung oligo-recurrence of non-small cell lung cancer: a retrospective analysis. Journal of Radiation Research. 63(2). 272–280. 9 indexed citations
5.
Fang, Jun, et al.. (2020). Prognostic value of immune checkpoint molecules in breast cancer. Bioscience Reports. 40(7). 95 indexed citations
6.
Yang, Yang, Xiaofang Xu, Xia Zhou, et al.. (2020). Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy. Frontiers in Oncology. 10. 1431–1431. 13 indexed citations
7.
Gu, Feiying, Yuxin Lin, Zhun Wang, et al.. (2020). Biological roles of LSD1 beyond its demethylase activity. Cellular and Molecular Life Sciences. 77(17). 3341–3350. 84 indexed citations
8.
Fang, Jun, Zhimin Ye, Feiying Gu, et al.. (2018). DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system. Oncology Letters. 16(2). 1869–1875. 19 indexed citations
9.
10.
Gu, Feiying, et al.. (2015). Analysis of Clinical and Dosimetric Factors Influencing Radiation-Induced Lung Injury in Patients with Lung Cancer. Journal of Cancer. 6(11). 1172–1178. 20 indexed citations
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026